Shares of Antares Pharma, Inc. (NASDAQ:ATRS) have been given an average recommendation of “Buy” by the six research firms that are currently covering the firm, Marketbeat.com reports. One investment analyst has rated the stock with a hold rating, three have given a buy rating and two have issued a strong buy rating on the company. The average 1 year price objective among brokers that have updated their coverage on the stock in the last year is $4.43.

Several research analysts recently commented on the stock. Chardan Capital began coverage on shares of Antares Pharma in a report on Friday, June 23rd. They issued a “buy” rating and a $5.00 price objective for the company. HC Wainwright reissued a “buy” rating and set a $5.00 target price on shares of Antares Pharma in a report on Sunday, September 10th. Vetr raised shares of Antares Pharma from a “hold” rating to a “buy” rating and set a $3.42 target price on the stock in a report on Tuesday, July 18th. Finally, Piper Jaffray Companies restated a “buy” rating on shares of Antares Pharma in a research report on Friday, September 8th.

Several institutional investors and hedge funds have recently made changes to their positions in ATRS. Asymmetry Capital Management L.P. purchased a new stake in shares of Antares Pharma in the second quarter worth about $643,000. California State Teachers Retirement System bought a new position in shares of Antares Pharma in the second quarter valued at approximately $820,000. Raymond James Financial Services Advisors Inc. bought a new position in shares of Antares Pharma in the second quarter valued at approximately $307,000. The Manufacturers Life Insurance Company boosted its position in shares of Antares Pharma by 1,188.2% in the second quarter. The Manufacturers Life Insurance Company now owns 121,633 shares of the specialty pharmaceutical company’s stock valued at $392,000 after acquiring an additional 112,191 shares during the period. Finally, Arrowstreet Capital Limited Partnership bought a new position in shares of Antares Pharma in the second quarter valued at approximately $174,000. Hedge funds and other institutional investors own 36.77% of the company’s stock.

Antares Pharma (NASDAQ ATRS) opened at 3.63 on Wednesday. The firm’s 50-day moving average price is $3.07 and its 200-day moving average price is $2.95. Antares Pharma has a 1-year low of $1.41 and a 1-year high of $3.73. The company’s market cap is $567.76 million.

Antares Pharma (NASDAQ:ATRS) last posted its quarterly earnings results on Tuesday, August 8th. The specialty pharmaceutical company reported ($0.02) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.03) by $0.01. The company had revenue of $13.42 million for the quarter, compared to analyst estimates of $12.99 million. Antares Pharma had a negative net margin of 34.27% and a negative return on equity of 41.37%. Equities research analysts forecast that Antares Pharma will post ($0.11) EPS for the current fiscal year.

WARNING: This piece of content was originally posted by American Banking News and is the sole property of of American Banking News. If you are reading this piece of content on another domain, it was copied illegally and reposted in violation of U.S. and international trademark and copyright legislation. The legal version of this piece of content can be accessed at https://www.americanbankingnews.com/2017/10/04/antares-pharma-inc-atrs-receives-consensus-rating-of-buy-from-analysts.html.

Antares Pharma Company Profile

Antares Pharma, Inc (Antares) is a specialty pharmaceutical company that focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies. The Company develops, manufactures and commercializes therapeutic products using its drug delivery systems. Its subcutaneous injection technology platforms include VIBEX disposable pressure-assisted auto injector system suitable for branded and generic injectable drugs in unit dose containers, reusable needle-free spring-action injector devices, and disposable multi-use pen injectors for use with cartridges.

Receive News & Ratings for Antares Pharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Antares Pharma Inc. and related companies with MarketBeat.com's FREE daily email newsletter.